Will AI Transform the Healthcare Industry for Investors?
To transform science fiction into reality, AI applications in the healthcare sector must prove that they can improve business profitability.
Read MoreBiotechnology
Market Smells Blood, Gives CSL a Whack
Shares in pharma giant CSL took a hit yesterday after it revealed a larger than forecast loss from currency movements for its FY2022-23.
Read MoreFinding Value in the Much-Hyped AI Space
Platinum’s Cameron Robertson and Dr Bianca Ogden discuss areas they have invested in and ones to watch in the always exciting tech space.
Read MoreSemiconductor Thematics Leading the Way
In this month’s Next Big Theme, Global X examines all the developments across thematics such as internet of things, green metals, AI and more.
Read MoreChimeric Therapeutics’ Portfolio of Cancer Therapies
Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an update on the clinical-stage cell therapy company’s recent therapy trials.
Read MoreACL Healius Bid Bordering on the Pathological
Even though the Covid testing boom is over, Australian Clinical Labs still wants to create the country’s largest pathology provider by taking over the number one tester, Healius.
Read MoreHealthcare: Boosting your defences?
JH’s Portfolio Construction & Strategy team explain why investors should consider a dedicated allocation to healthcare, which has historically captured less downside during sell-offs.
Read MoreImmutep (ASX: IMM) Delivering Strong Lung Cancer Data
Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses data from the SITC Conference in Boston, the strategy to take Efti to market and milestones for 2023.
Read MoreRadiopharm Theranostics (ASX: RAD) Eyes NASDAQ Listing
Radiopharm Theranostics Limited CEO / MD Riccardo Canevari discusses the company’s upcoming plans to list on the NASDAQ and provides an update on its clinical trials.
Read MoreMemphasys (ASX: MEM) Felix System Findings
Memphasys (ASX: MEM) has announced the first publications of study findings by key opinion leaders of the Felix System.
Read MoreHealthcare Stocks Show Signs of Strength
Andy Acker from JH says healthcare’s defensive qualities could help the sector outperform the broader equity market, while biotech could offer pockets of growth.
Read MoreImmutep (ASX: IMM) – A Transformative Year for LAG-3 Therapies
Immutep CEO Marc Voigt discusses the LAG-3 landscape, the company’s portfolio of therapies, encouraging data from the 2022 SITC conference and the outlook for 2023.
Read MoreRadiopharm Theranostics (ASX: RAD) to commence NSCLC trial in Australia
Radiopharm Theranostics MD / CEO Riccardo Canevari discusses the progress of the company’s brain, lung and prostate cancer therapies with FNN’s Lauren Hayes.
Read MoreGenetic Signatures (ASX: GSS) – Detecting Infectious Diseases in High-Throughput Lab Workflows
Genetic Signatures Limited CEO and Director Dr John Melki discusses the healthcare company’s technology, business model, 2022 highlights and outlook.
Read MoreArovella Therapeutics (ASX: ALA) – Tackling blood cancers and solid tumours
Arovella Therapeutics Limited Managing Director and CEO Dr Michael Baker provides an update on what’s been happening at the biotech company.
Read MoreOncoSil Medical (ASX: OSL) – Targeted therapy for pancreatic cancer
OncoSil Medical Limited Non-Executive Director Brian Leedman discusses joining the board of OncoSil and receiving CE mark approval for the company’s therapy.
Read MoreBiotechs Preparing for the Next Chapter of Growth
Platinum’s Dr Bianca Ogden explains why, contrary to popular perception at the moment, she believes the biotech sector is actually in pretty good shape.
Read MoreChimeric Therapeutics (ASX: CHM) enters research agreement to advance cell therapy portfolio
Chimeric Therapeutics CEO and Managing Director Jennifer Chow discusses the company’s new agreement with Case Western Reserve University.
Read MoreAntisense (ASX: ANP) Discuss Upcoming AGM & New Appointment
Antisense Chair Dr Charmaine Gittleson and new Chief Commercial Officer Dr Anthony Filippis discuss attracting new talent to the company and what drew Dr Filippis to the role.
Read MoreImmutep (ASX: IMM) Receives Fast Track Designation from FDA
Immutep CEO Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company’s new Phase 2 trial in soft tissue sarcoma and the outlook ahead.
Read MoreArovella Therapeutics (ASX:ALA) partners with Imugene (ASX:IMU)
Arovella Therapeutics Limited (ASX:ALA) Managing Director and CEO Michael Baker discusses the company’s collaboration with Imugene to combine therapies.
Read MoreRadiopharm Theranostics (ASX:RAD) Receives FDA Designations for DUNP19
Radiopharm Theranostics CEO and Managing Director Riccardo Canevari discusses the FDA’s award of orphan status and rare paediatric disease designation for the company’s DUNP19 technology.
Read MoreTech Talk: Better than feared?
Alphinity’s Trent Masters analyses the reporting season that wasn’t quite as bad as people feared, earnings expectations for this year and next and the divergence in technology.
Read MoreAntisense Therapeutics (ASX:ANP) – Revised Clinical Plans Presentation
Antisense Therapeutics CEO /MD Mark Diamond and Chair Charmaine Gittleson discuss the company’s revised clinical development plans for Duchenne’s Muscular Dystrophy.
Read MoreGlobal Biotech Turnaround Looks to Be Underway
Signs of life are emerging in the global biotech sector after the longest and sharpest downturn in history that was so severe it left hundreds US companies trading below cash backing.
Read MoreKazia: AGILE Hurdle Missed but Significant Value Remains
Corporate Connect analyst Marc Sinatra has today released an updated research report for ASX-listed biotech company Kazia Therapeutics (ASX: KZA), now available for download.
Read MoreTech Talk: A difficult reporting season ahead
In this month’s Tech Talk, Trent Masters from Alphinity IM reflects on the last month in markets and looks ahead to what’s set to be the most difficult reporting season in recent times.
Read MoreRadiopharm Theranostics (ASX:RAD) to start prostate cancer trial
Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an update on the company’s portfolio of therapies.
Read MoreImmutep (ASX:IMM) granted Japanese patent for IMP761
Immutep (ASX:IMM) has granted a Japanese patent for its IMP761, an immunosuppressive agonist antibody targeting LAG-3 for autoimmune diseases.
Read MoreBiotech, Down but Absolutely Not Out
It has been a difficult 12 months or so for biotech, but Platinum Asset Management Portfolio Manager Dr Bianca Ogden believes the sector is “absolutely not broken” – far from it.
Read MoreTech Talk: From hiring to firing
In this month’s edition of Tech Talk, Trent Masters from Alphinity Investment Management explores the highlights in the tech landscape from his recent trip to the US.
Read MoreImmutep (ASX:IMM) TACTI-002 data presented at ASCO 2022
Immutep Limited ED / CEO Marc Voigt, Chief Scientific and Medical Officer Dr Frédéric Triebel, and Vice President Strategic Development Christian Mueller present on Immutep’s latest clinical results.
Read MoreImmutep Limited (ASX:IMM) Investor Presentation
Immutep Limited CEO Marc Voigt provides an overview of the company, discussing the LAG-3 immune checkpoint and pipeline, eftilagimod alpha’s potential, and ongoing clinical trials.
Read MoreChimeric Therapeutics (ASX:CHM) Expands Cancer Trials
Chimeric Therapeutics CEO / MD Jennifer Chow provides an update on clinical trial progression and discusses recent agreements with WuXi Advanced Therapies and Be The Match BioTherapies.
Read MoreRadiopharm Theranostics: Developing a portfolio of assets targeting cancer
Radiopharm Theranostics Limited CEO and Managing Director Riccardo Canevari provides an update on the company’s pipeline and discusses the recent licensing of an asset from UCLA.
Read MoreSuperbugs Are Outsmarting Antibiotics
As Magellan Investment Specialist Michael Collins explains, a market failure means pharmaceutical companies are failing to address the threat of increasingly drug-resistant “Superbugs”.
Read MoreHow Immutep Treats Head & Neck Cancer
ShareCafe spoke with Marc Voigt, CEO of local biotech Immutep, about the progress his company is making specifically in the area of head and neck cancer treatments.
Read MoreKey Points To Remember When Investing in Biotech Companies
As part of his latest research report on the biotech sector, Corporate Connect analyst Marc Sinatra gives some insights into what to consider when making an investment in this space.
Read MoreCustody Battle Drags on for Virtus Health
The battle for IVF operator Virtus continues, with Australian private equity group BGH upping its offer price to $7.65 per share as it goes head-to-head with London based rival CapVest.
Read MoreNovartis, US Political Risks and Investing in Cancer Research
Magellan’s John Wylie reviews Novartis, looks at US political risks to the healthcare sector, and addresses how cancer research innovation may translate to investment profits.
Read More
